EUVIMEDEUVIMED entdecken
Klinische StudieOpen Access · CC BY 4.0

Low-dose naltrexone as an adjunctive treatment for major depressive disorder: findings from a randomized, double-blind, placebo-controlled hybrid parallel-arm study

Ben D Moloney, Anna Forsyth, Rachael L Sumner, Stephanie C Glover, Nicholas R Hoeh, Frederick Sundram, Alana Cavadino, Suresh Muthukumaraswamy, Joanne C Lin

Frontiers in Pharmacology · 06.03.2026 · 17

DOI: 10.3389/fphar.2026.1767654 ↗

Kurz gefasst

Klinische Studie in der Zeitschrift Frontiers in Pharmacology, online erschienen am 06.03.2026. Verfasst von Ben D Moloney und 8 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Health Research Council of New Zealand.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Major depressive disorder (MDD) is a leading cause of global disability. Current treatments are limited by poor efficacy in approximately one-third of patients. Neuroinflammation may be an underlying mechanism of MDD and represents a novel target for pharmacological therapy. This study aimed to investigate the effects of a putative centrally acting anti-inflammatory agent, low-dose naltrexone (LDN), in MDD.

Methods

Patients with MDD experiencing moderate depressive symptoms and receiving antidepressant treatment were randomized to receive 12 weeks of LDN (up to 4.5 mg per day) or 12 weeks of inactive placebo. The primary outcome measure was the Montgomery-Asberg Depression Rating Scale (MADRS) at 12 weeks, analyzed using a linear mixed-effects model adjusted for baseline.

Results

Thirty-seven patients were randomized. At 12 weeks, MADRS scores (M ± SD) were reduced by 10.5 ± 5.6 in the LDN group and 9.8 ± 5.9 placebo group; with no difference between groups (p = 0.97). LDN did not affect high-sensitivity C-reactive protein (hsCRP) levels or exploratory measures of depression, behavioral activation, quality of life, sickness symptoms and mood. There was no evidence that baseline hsCRP modified the effect of LDN on MADRS score.

Discussion

Adjunctive LDN does not appear to alter depressive symptoms in moderate MDD. Larger studies are warranted to evaluate LDN in a population with a higher likelihood of neuroinflammatory pathology, such as those with severe, treatment-resistant MDD or comorbid inflammatory conditions. Future studies should utilize stratification tools that are more sensitive and specific to neuroinflammation than hsCRP. Clinical Trial Registration https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=383741&isReview=true , identifier [ACTRN12622000881730].

Schlagwörter

Stichwörter der Autor:innen

C-reactive proteininflammationmajor depressive disordernaltrexonerct

Autor:innen und Institutionen

  • School of Pharmacy, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand.
  • Department of Biomedicine and Medical Diagnostics, Auckland University of Technology, Auckland, New Zealand.
  • Department of Psychological Medicine, School of Medicine, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand.
  • Department of Epidemiology and Biostatistics, School of Population Health, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand.

Förderung

  • Health Research Council of New Zealand

Zitieren

APA

Moloney, B. D., Forsyth, A., Sumner, R. L., Glover, S. C., Hoeh, N. R., Sundram, F., Cavadino, A., Muthukumaraswamy, S., & Lin, J. C. (2026). Low-dose naltrexone as an adjunctive treatment for major depressive disorder: findings from a randomized, double-blind, placebo-controlled hybrid parallel-arm study. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1767654

Vancouver

Moloney BD, Forsyth A, Sumner RL, Glover SC, Hoeh NR, Sundram F, et al. Low-dose naltrexone as an adjunctive treatment for major depressive disorder: findings from a randomized, double-blind, placebo-controlled hybrid parallel-arm study. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1767654

BibTeX
@article{Moloney2026,
  author = {Moloney, Ben D and Forsyth, Anna and Sumner, Rachael L and Glover, Stephanie C and Hoeh, Nicholas R and Sundram, Frederick and Cavadino, Alana and Muthukumaraswamy, Suresh and Lin, Joanne C},
  title = {Low-dose naltrexone as an adjunctive treatment for major depressive disorder: findings from a randomized, double-blind, placebo-controlled hybrid parallel-arm study},
  journal = {Frontiers in Pharmacology},
  year = {2026},
  volume = {17},
  doi = {10.3389/fphar.2026.1767654}
}
Kostenlos starten →